Phase II study of neoadjuvant chemoradiation therapy with cisplatin plus fluorouracil for esophageal cancer - Phase II study of neoadjuvant chemoradiation therapy with cisplatin plus fluorouracil for esophageal cancer

Maeda Osamu0 个研究点目标入组 12 人开始时间: 2018年9月11日最近更新: 2023年11月20日

适应症

试验速览

Twelve patients received chemoradiotherapy and 11 underwent esophagectomy. Side effects were manageable.

•1.ECOG PS 0-1
•2.Endoscopic biopsy of esophageal primary lesion histologically diagnosed as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma or basal cell carcinoma.
•3. Any of the following based on TNM classification (UICC-TNM 7 th edition)
•1) cStage IB
•2) cStage II
•3) cStage III Infiltration into the trachea at the cervical /cervical chest boundary (T4) is eligible. Excluding other T4. So-called borderline-resectable T4 disease, not clearly diagnosed as T4, is eligible.
•4) cStage IV with supraclavicular lymph node metastasis and without other distant metastasis.
•4. Adequate organ function.

•1) Clear T4 other than invasion of cervical / cervical gastrointestinal tract esophageal cancer
•2) Distant metastasis to other than supraclavicular lymph nodes.
•3) Esophagogastric junction lesion of which main lesion is located in the stomach rather than the esophagus.
•4) Judged not to be eligible by the researchers

发起方

Maeda Osamu